I like the hammering we are all giving to the spanking alphalfa idiot,zero positive comments:
Igraduatedcollegealready!
Notice author won’t respond to comments
16 May 2019, 12:57 PM Reply2Like
aaronak1032
I wonder who this person knows that was about to get squeezed and how much they had on the line.
16 May 2019, 12:05 PM Reply2Like
mako66
Bullshit article. You do not have the slightest idea of ??biotechnology stocks, right?
Shorting CVM could get a financial nightmare...
16 May 2019, 11:51 AM Reply3Like
shawn1726
This article emphasis on the negative side more so on positive. Of course there are risks . Otherwise the stock should be in $40 - $ 60 range.
It seems that they finally after all these years, they got this. For them to raise cash if needed at this stage is no problem. To make a partnership also np . The risk and reward is definitely warranted. worth the risks.
16 May 2019, 11:30 AM Reply5Like
J Tull
cvm cured/ eliminated 10% in phase 2
16 May 2019, 11:19 AM Reply6Like
Ron Dupard
You mean to tell me that seeking alpha actually pays you to write this half researched and clearly biased horseshit?
16 May 2019, 11:17 AM Reply7Like
BiotechX
Comments1035 | + Follow
You demonstrated nicely in your article that you are either short on Cel-Sci and your article will make some investors nervous or you don't have a clue about the nature of biotech companies or both?
However, that what you call "the Dangers of Cel-Sci" are more or less the dangers of all biotechs in a development stage. Not too miuch cash is not so nice, ok, but a valuation of $250M for a company with a PhIII trial in the final stages is completely fine and you should know this. The market will give Cel-Sci a new price tag after they report their PIII results and it will be somewhere between -80 % to +150% from their current valuation.
That's biotech business.
In conclusion: Your article is a waste of time.
16 May 2019, 11:17 AM Reply10Like
fantasysportsgod1111
wow! you left out tons of relevant information my friend and you used true information out of context. maybe I'm incorrectly interpreting the intent of your article. but it seems to have a odd spin to it. I respectfully disagree with your sentiment good sir.
16 May 2019, 11:15 AM Reply6Like
matherapist
What you say is total garbage. Stick to something you understand like fertilizer manufacturing.
16 May 2019, 11:12 AM Reply7Like
Ron Dupard
????????????
16 May 2019, 11:21 AM Reply0Like
goestock
This is a very promising drug, potentially the best one out there, if you ever spent time studying. Maybe people like you should never get access to it.
16 May 2019, 10:56 AM Reply5Like
nick 88
no mention of the 210k of insider purchases at around 6.86 just last month? It's a multi-billion opportunity with a company that has a MC of 250m and more than a 50:50 chance of success, the fact the study has still not completed is what suggests patients are surviving longer and the drug is working, hence the rise in the share price.
16 May 2019, 10:49 AM
Igraduatedcollegealready!
Appreciate the time you took to wrote the article and there is a lot of facts in what you write but I think your article makes clear that you don’t understand valuation.
The company had a 75 million market cap for a potential phase 3 drug approval with a timetable of this year. Whether it’s positive or negative, there is significant value for the potential. This is why the stock traded so significantly that it created awareness of a company with a potential multi-billion drug in phase 3 trading under 100 million market cap.
So the risk reward is off the charts. If the trial is negative, the stock trades under $1.00. If the trial is positive, there is high probability the stock trades over $20 in one day and then could ultimately trade over 30-50 by year end with drug approval.
My point being is your article is very short sighted and narrow minded. It doesn’t really make sense to write this article unless you are short or someone you know is short.
16 May 2019, 10:45 AM
News 
Market Data 
Discover 
